Register Financial Advisors LLC Has $830,000 Stake in Eli Lilly and Company (NYSE:LLY)

Register Financial Advisors LLC grew its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 6.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,067 shares of the company’s stock after acquiring an additional 61 shares during the period. Register Financial Advisors LLC’s holdings in Eli Lilly and Company were worth $830,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Trexquant Investment LP bought a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at $3,874,000. Morningstar Investment Services LLC increased its position in Eli Lilly and Company by 112.8% in the 3rd quarter. Morningstar Investment Services LLC now owns 1,741 shares of the company’s stock valued at $948,000 after buying an additional 923 shares in the last quarter. Cape Cod Five Cents Savings Bank increased its position in Eli Lilly and Company by 101.6% in the 3rd quarter. Cape Cod Five Cents Savings Bank now owns 5,126 shares of the company’s stock valued at $2,753,000 after buying an additional 2,583 shares in the last quarter. CWA Asset Management Group LLC raised its stake in Eli Lilly and Company by 13.9% during the 3rd quarter. CWA Asset Management Group LLC now owns 2,465 shares of the company’s stock worth $1,324,000 after buying an additional 300 shares during the period. Finally, Teza Capital Management LLC bought a new position in Eli Lilly and Company in the third quarter worth approximately $4,313,000. 82.53% of the stock is owned by institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 92,563 shares of the stock in a transaction on Friday, May 24th. The stock was sold at an average price of $809.21, for a total transaction of $74,902,905.23. Following the completion of the transaction, the insider now owns 98,556,247 shares in the company, valued at approximately $79,752,700,634.87. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, major shareholder Lilly Endowment Inc sold 92,563 shares of the company’s stock in a transaction that occurred on Friday, May 24th. The shares were sold at an average price of $809.21, for a total transaction of $74,902,905.23. Following the sale, the insider now directly owns 98,556,247 shares in the company, valued at approximately $79,752,700,634.87. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Donald A. Zakrowski sold 750 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the transaction, the chief accounting officer now directly owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The disclosure for this sale can be found here. Insiders have sold a total of 789,704 shares of company stock worth $672,385,964 over the last ninety days. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Price Performance

LLY opened at $905.87 on Friday. Eli Lilly and Company has a fifty-two week low of $434.34 and a fifty-two week high of $915.54. The firm has a 50-day moving average of $814.40 and a 200 day moving average of $738.79. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. The firm has a market cap of $860.95 billion, a P/E ratio of 133.41, a PEG ratio of 1.98 and a beta of 0.36.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. During the same period in the prior year, the firm earned $1.62 EPS. The company’s revenue was up 26.0% compared to the same quarter last year. On average, research analysts expect that Eli Lilly and Company will post 13.76 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 0.57%. The ex-dividend date of this dividend is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on LLY shares. JPMorgan Chase & Co. boosted their price objective on Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. Argus boosted their price target on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a research note on Tuesday, May 14th. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Cantor Fitzgerald reissued an “overweight” rating and set a $885.00 target price on shares of Eli Lilly and Company in a research report on Monday, June 24th. Finally, The Goldman Sachs Group upped their target price on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $812.72.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.